Hansa Biopharma (Q1 update): Soft Quarter Creates Opportunity - Redeye

Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK35m (SEK66m). IDEFIRIX sales amounted to SEK34m. This was a significant decline Y/Y and Q/Q and below our forecast, although we had expected a soft quarter. However, several improvements in the commercial landscape and near-term data readouts position the company for growth in Europe for the full year 2026. We believe the current low share price creates an attractive entry point, both for short- and long-term investors.

Länk till analysen i sin helhet: https://www.redeye.se/research/1160671/hansa-biopharma-q1-update-soft-quarter-creates-opportunity?utm_source=finwire&utm_medium=RSS